Folotyn for Non-Hodgkin's Lymphoma Rome NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

Anthony G Lawrence
(315) 624-4300
1676 Sunset Ave
Utica, NY
MANZURUL SIKDER, MD
(315) 798-1500
1729 Burrstone Road
New Hartford, NY
Samir Devendra Desai, MD
315-798-9300
807 Newell St
Utica, NY
Teresa Caroline Gentile, MD
603 Seneca St Ste 2
Oneida, NY
Maria Arsyl D De Jesus, MD
315-363-4542
605 Seneca St
Oneida, NY
Atul V Butala
(315) 798-9300
807 Newell Street
Utica, NY
SULTANA RAZIA, MD
(315) 798-1700
1729 Burrstone Road
New Hartford, NY
SAMIR DESAI, MD
(315) 798-9300
807 Newell Street
Utica, NY
Alicia M Detraglia, MD
315-724-2177
6 Hampden Pl
Utica, NY
Lisa Ann Mueller, MD
914-830-9581
1514 Genesee St Apt 50
Utica, NY
Data Provided by:
    

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Donor Stem-Cell Transplant for Acute Myeloid Leukemia Rome NY
For most patients with acute myeloid leukemia (AML) who come out of remission, donor stem cells appear to offer the best shot at survival, a new analysis shows.
- Green Tea and Hematologic Malignancies Rome NY